CMSC: Consortium of Multiple Sclerosis Centers
Conference Coverage
High-efficacy DMTs may reduce depressive symptoms in MS
SEATTLE – Higher-efficacy DMTs may have antidepressive properties, possibly because of their anti-inflammatory...
Conference Coverage
Patients with MS who consider using marijuana are more likely to engage in risky behaviors
SEATTLE – Discussions of marijuana use should include discussions of health behaviors.
Conference Coverage
Mental illness in MS: ‘Follow the why’
SEATTLE - Unique challenges face physicians and patients, Dr. Laura T. Safar cautions.
Conference Coverage
Low baseline heart rate may not increase cardiac risk when starting fingolimod
SEATTLE – First-dose cardiac events with fingolimod are rare, regardless of whether first-dose observations occur in clinic or at home.
Conference Coverage
Group creates three-step algorithm for the management of MS relapse
SEATTLE – Distinguishing a multiple sclerosis relapse from a pseudorelapse is essential, according to a consensus statement.
Conference Coverage
Fingolimod reduces MS disease activity, compared with glatiramer acetate
SEATTLE – In patients with relapsing multiple sclerosis, 0.5 mg/day fingolimod reduces the annualized relapse rate...
Conference Coverage
Hazardous cannabis use in MS linked to anxiety, depression
SEATTLE – But it is not clear if there is a cause-and-effect relationship.
Conference Coverage
Adherence to oral treatments for MS is poor
SEATTLE – One in three patients with MS has a lapse in oral therapy that lasts for at least 30 days, and...
Conference Coverage
Extended-release arbaclofen reduces MS-related spasticity
SEATTLE – A regimen of twice-daily, extended-release arbaclofen could reduce the adverse events associated with...
Conference Coverage
Why aren’t preferred DMTs prescribed for MS? Neurologists point to insurers, patients
SEATTLE – Survey pinpoints reasons why various types of MS therapies aren’t initiated.
Conference Coverage
Modest evidence for benefit in studies of cannabis in MS
SEATTLE – Trials vary widely in quality, review finds, and most focused on Sativex.
Conference Coverage
What other drugs do patients take when they start MS therapy?
SEATTLE – Concomitant medication use is common when patients with multiple sclerosis start disease-modifying drugs (DMDs).
Latest News
Periodic limb movements during sleep are common in patients with MS and fatigue
SEATTLE – Sleep apnea may not be the only comorbidity that causes fatigue in multiple sclerosis, and treating...
Conference Coverage
Pain, fatigue, depression, and anxiety are common in the year after MS diagnosis
SEATTLE – In a novel study, about half of patients with multiple sclerosis reported clinically significant symptoms of depression or pain, and...
Conference Coverage
Age may influence choice of behavioral therapy to improve sleep in MS
SEATTLE – Few studies have examined the relationships between physical activity, sedentary behavior, and sleep...